In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Human Genome Sciences: Innovative Partnering for Innovative Technology

Executive Summary

Even with the funds from its $125 million SmithKline collaboration (which, at the time of its signing, was an unprecedented investment in a biotech licensing), HGS needs plenty more collaborations if it is going to outlive the century. In its joint venture deals with Genetic Therapy Inc. and Isis, HGS is focusing on a strategy of finding third-party licensees, not letting these biotechs create proprietary products themselves.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts